Research and Clinical Trials

Title  

MedImmune D5760C00001: A Phase 1 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2-expressing Advanced Solid Tumor

Brief Description  

The primary objective is to assess the safety, describe the DLTs, and determine the MTD or the maximum administered dose (MAD; in the absence of exceeding the MTD) for MEDI4276 administered as a single agent in subjects with HER2-expressing advanced breast or gastric cancer refractory to standard therapy or for which no standard therapy exists.

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Breast

Status  

OPEN

Start Date  

04/27/2016

IRB Number  

00016397

Principal Investigator  

Tan, Antoinette Roslyn

Contact Name  

Tesa M Adams

For More Information, Contact  Tesa  M, Adams
Phone:  980-442-2335 Fax:    
Email:  Tesa.Adams@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204